Business Wire

 Vertex Confirms Northern Ireland Offer Accepted for Cystic Fibrosis Medicines

Share

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirms that the Regional Pharmaceutical Procurement Service in Northern Ireland has accepted an offer for access to all currently licensed Vertex cystic fibrosis (CF) medicines and any future indications of these medicines under the same terms as the recently announced agreement with NHS England.

This means that once the contract is finalized, patients with CF in Northern Ireland ages 2 years and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene will have access to ORKAMBI ® (lumacaftor/ivacaftor) and CF patients ages 12 years and older who either have two copies of the F508del mutation or one copy of the F508del mutation and a copy of one of the other 14 licensed mutations will have access to SYMKEVI® (tezacaftor/ivacaftor) in combination with ivacaftor. We will support the arrangements being put in place to ensure clinicians will be able to prescribe to eligible patients within the next few weeks.

The agreement also offers expanded access to KALYDECO ® (ivacaftor) to include people ages 18 years and older who have the R117H mutation and those patients ages 12 months and older who have one of the nine licensed gating mutations.

“We are pleased that the nearly 280 eligible cystic fibrosis patients in Northern Ireland will soon have access to CFTR modulators to treat the underlying cause of their disease and we thank the authorities in Northern Ireland for their collaboration and commitment in this agreement,” said Ludovic Fenaux, Senior Vice President, Vertex International.

About CF in the UK
Over 10,000 people in the UK have CF — the second highest number in the world. Nearly 480 people in Northern Ireland have CF. CF is a debilitating, life-shortening inherited condition that causes progressive damage to organs across the body from birth. Currently, there is no cure for CF and half of people in the UK with CF die before they are 32. The daily impact of treatment is significant. It can take up to four or more hours, involving nebulizers, physiotherapy and up to 70 tablets a day. CF accounts for 9,500 hospital admissions and over 100,000 hospital bed days a year. A third of these are used by children under 15.

About ORKAMBI® (lumacaftor/ivacaftor) and the F508del mutation
In people with two copies of the F508del mutation, the CFTR protein is not processed and trafficked normally within the cell, resulting in little-to-no CFTR protein at the cell surface. Patients with two copies of the F508del mutation are easily identified by a simple genetic test.

Lumacaftor/ivacaftor is a combination of lumacaftor, which is designed to increase the amount of mature protein at the cell surface by targeting the processing and trafficking defect of the F508del-CFTR protein, and ivacaftor, which is designed to enhance the function of the CFTR protein once it reaches the cell surface.

For complete product information, please see the Summary of Product Characteristics that can be found on www.ema.europa.eu.

About SYMKEVI® (tezacaftor/ivacaftor) in combination with ivacaftor
Some mutations result in CFTR protein that is not processed or folded normally within the cell, and that generally does not reach the cell surface. Tezacaftor is designed to address the trafficking and processing defect of the CFTR protein to enable it to reach the cell surface and ivacaftor is designed to enhance the function of the CFTR protein once it reaches the cell surface.

SYMKEVI is indicated for people with CF ages 12 and older who either have two copies of the F508del mutation or one copy of the F508del mutation and have one of the following 14 mutations in which the CFTR protein shows residual function: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, or 3849+10kbC→T.

For complete product information, please see the Summary of Product Characteristics that can be found on www.ema.europa.eu.

About KALYDECO® (ivacaftor)
KALYDECO® (ivacaftor) is the first medicine to treat the underlying cause of CF in people with specific mutations in the CFTR gene. Known as a CFTR potentiator, ivacaftor is an oral medicine designed to keep CFTR proteins at the cell surface open longer to improve the transport of salt and water across the cell membrane, which helps hydrate and clear mucus from the airways.

KALYDECO is indicated in people ages 12 months and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. KALYDECO is also indicated for the treatment of patients with CF ages 18 years and older who have an R117H mutation in the CFTR gene.

For complete product information, please see the Summary of Product Characteristics that can be found on www.ema.europa.eu.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has four approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational medicines in other serious diseases where it has deep insight into causal human biology, such as sickle cell disease, beta thalassemia, pain, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and APOL1-mediated kidney diseases.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London, UK. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 10 consecutive years on Science magazine's Top Employers list and top five on the 2019 Best Employers for Diversity list by Forbes.

Special Note Regarding Forward-looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, the statements by Mr. Fenaux in the fourth paragraph of this press release and statements regarding our expectations for the patient populations that will be able to access Vertex’s medicines and the timing of such access. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy or other reasons, and other risks listed under Risk Factors in Vertex's annual report and subsequent quarterly reports filed with the Securities and Exchange Commission and available through the company's website at www.vrtx.com. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

Contact information

Vertex Pharmaceuticals Incorporated
UK Media: +44 20 3204 5275
MediaInfo@vrtx.com

U.S. Media: 617-341-6992
MediaInfo@vrtx.com

Investors: 617-961-7163
InvestorInfo@vrtx.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Citi Private Bank Hails Fernando Alonso on His Impressive Maiden Dakar Rally20.1.2020 20:00:00 EETPress release

Citi Private Bank-sponsored motorsports legend, Fernando Alonso, has electrified his fans with his debut performance in one of the toughest motorsports-endurance events, the Dakar Rally. The multiple world champion finished fourth in the race’s final stage, and was the leading newcomer overall. This marked an impressive comeback from the difficulties he experienced earlier in the week, when his car suffered wheel and suspension damage, as well as a later double-roll crash. The annual Dakar Rally – now in its forty-second year – is an extreme off-road endurance race. This year’s edition consisted of twelve daily stages covering a total of 7,500 kilometers (4,600 miles). As well as a contest between some of the world’s top drivers, the Dakar Rally pits drivers against grueling terrains. In 2020, drivers faced the additional challenge of receiving information about the course on the mornings of certain legs of the race, rather than the day before. “Fernando’s tenacious performance in his

Keio Plaza Hotel Tokyo Hosts “Hina-Matsuri” Girls’ Doll Festival Art Exhibition20.1.2020 17:05:00 EETPress release

Keio Plaza Hotel Tokyo (KPH), one of Japan’s most prestigious international hotels located in Shinjuku, Tokyo, will host an event entitled “Hina-Matsuri Girls’ Doll Festival Art Exhibition” to help guests celebrate Japan’s cultural event known as Girls’ Doll Festival or Hina-Matsuri from February 1 to March 26, 2020. This highly popular event is held annually and displays some 6,800 magnificent and ornate hanging art ornaments made by hand from old silk cloth. These ornaments are carefully crafted for this exhibition and symbolically reflect the hopes for health and happiness of children. Also, peach flowers are featured as a theme for exhibition, concerts and workshops in this year’s event in keeping with the “Peach Festival” and the belief that peaches lead to longevity as they drive off evil spirits. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200120005118/en/ About 6,800 hanging ornaments, each one handmade from kimon

ResMed Introduces AirFit F30i, Its First Tube-up Full Face CPAP Mask20.1.2020 17:00:00 EETPress release

ResMed (NYSE: RMD) (ASX: RMD) today introduced AirFit F30i, its first tube-up full face CPAP mask, rounding out the most complete full face mask portfolio on the market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200120005042/en/ AirFit F30i tube-up full face mask, front view (Photo: Business Wire) Full face CPAP users can now choose between a tube-up or tube-down connection, compact under-the-nose or traditional over-the-nose cushion styles, and even memory foam versus silicone cushion. AirFit F30i’s tube-up design makes it easier to sleep in any position. The cushion rests under the nose to help prevent next-day red marks, soreness, and irritation on the nasal bridge. Plus, a quick-release elbow allows users to quickly disconnect and reattach the mask from its tubing at night without taking the mask off. Three out of four CPAP users prefer AirFit F30i to its competitor’s tube-up full face mask for overall performance i

xx network Announces Support of Early Backers of xx coin Sale20.1.2020 17:00:00 EETPress release

The xx network has announced support of crypto pioneers, including Chris Larsen, for the initial Cayman sale of the xx coin starting on January 23, 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200120005068/en/ xx network photo (Photo: Business Wire) The xx coin is a quantum secure digital currency designed to support and incentivize the decentralized ecosystem of the xx network, the revolutionary privacy-protecting blockchain led by David Chaum, founder of the Elixxir and Praxxis projects which underpin the xx network. Chris Larsen, a serial entrepreneur, co-founder of the Ripple Network and longtime advocate for consumer privacy, said, "David Chaum has been a defender of privacy in the digital world for almost forty years. I am proud to be an early backer and look forward to seeing this consumer-facing blockchain open the door to secure use by millions of individuals in their daily lives." Ownership and control of t

Wipro Positioned as a Leader in Networks - Software Defined Solutions and Services for UK and Nordics20.1.2020 16:56:00 EETPress release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has been positioned as a Leader in ISG Provider Lens™: Network - Software Defined Solutions and Services quadrant report for Nordics and the U.K. The reports were authored by Avimanyu Basu. ISG recognized Wipro after evaluating the capabilities of 153 providers across seven quadrants: Managed WAN Services; Mobile Network (4G/5G) Additional (non-core) Services; SDN Transformation Services (Consulting and Implementation); SD-WAN Equipment and Services (DIY); SDN Security Services; SD Network Technologies (Core), and SD Network Technologies (Mobile to Edge). Wipro has been named a ‘Leader’ in Managed WAN Services, SDN Transformation Services (Consulting & Implementation), SDN security services, SD Network Technologies (Core) and SD Network Technologies (Mobile to Edge) quadrant in the ISG Provider Lens™: Network - Software D

Wipro Positioned as a Global Market Leader in Software Defined Network Solutions and Services by ISG20.1.2020 16:24:00 EETPress release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has been positioned as a Leader in ISG Provider Lens™: Network - Software Defined Solutions and Services Global 2019 quadrant report authored by Kenn Walters. The ISG Provider Lens™ Network – Software Defined Solutions and Services Global 2019 quadrant report evaluates the capabilities of 153 providers across seven quadrants: Managed WAN Services; Mobile Network (4G/5G) Additional (non-core) Services; SDN Transformation Services (Consulting and Implementation); SD-WAN Equipment and Services (DIY); SDN Security Services; SD Network Technologies (Core), and SD Network Technologies (Mobile to Edge). It highlights that Wipro produces highly innovative solutions backed by expertise, toolsets, methods and processes, including Artificial Intelligence (AI) & Robotic process Automation (RPA), and is an important provider of advanc

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom